X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (718) 718
animals (389) 389
depsipeptides - pharmacology (314) 314
oncology (282) 282
depsipeptides - therapeutic use (263) 263
female (240) 240
pharmacology & pharmacy (230) 230
depsipeptides (226) 226
male (219) 219
histone deacetylase inhibitors (200) 200
cancer (187) 187
mice (166) 166
antineoplastic agents - therapeutic use (162) 162
apoptosis (159) 159
antineoplastic agents - pharmacology (148) 148
depsipeptide (145) 145
cell line, tumor (138) 138
depsipeptides - chemistry (138) 138
histone deacetylase inhibitor (138) 138
middle aged (133) 133
aged (124) 124
adult (121) 121
chemistry, medicinal (114) 114
depsipeptides - administration & dosage (112) 112
neoplasms - drug therapy (110) 110
apoptosis - drug effects (107) 107
depsipeptide fr901228 (106) 106
biochemistry & molecular biology (101) 101
suberoylanilide hydroxamic acid (100) 100
histone deacetylase inhibitors - therapeutic use (97) 97
dose-response relationship, drug (96) 96
romidepsin (95) 95
expression (91) 91
histone deacetylase inhibitors - pharmacology (91) 91
antibiotics, antineoplastic - therapeutic use (88) 88
peptides (85) 85
treatment outcome (85) 85
acetylation (84) 84
in-vitro (83) 83
microbiology (83) 83
histone deacetylases - metabolism (81) 81
peptides, cyclic - therapeutic use (80) 80
hematology (79) 79
molecular structure (76) 76
depsipeptides - adverse effects (73) 73
biology (72) 72
research (72) 72
anti-bacterial agents - therapeutic use (70) 70
histone deacetylase (69) 69
antineoplastic combined chemotherapy protocols - therapeutic use (68) 68
enzyme inhibitors - pharmacology (67) 67
fk228 (67) 67
anti-bacterial agents - pharmacology (65) 65
health aspects (63) 63
t-cell lymphoma (62) 62
antineoplastic agents (61) 61
cell proliferation - drug effects (61) 61
clinical trials as topic (61) 61
care and treatment (60) 60
chemotherapy (59) 59
drug therapy (58) 58
immunology (58) 58
peptides, cyclic - pharmacology (58) 58
antineoplastic agents - chemistry (57) 57
tumor cells, cultured (57) 57
analysis (55) 55
gene expression (55) 55
antibiotics, antineoplastic - pharmacology (54) 54
histones - metabolism (54) 54
proteins (53) 53
enzyme inhibitors - therapeutic use (51) 51
phase-i (51) 51
phase-ii trial (50) 50
structure-activity relationship (50) 50
antibiotics (49) 49
drug synergism (48) 48
hdac inhibitors (48) 48
vorinostat (48) 48
aged, 80 and over (47) 47
cell survival - drug effects (47) 47
tumors (47) 47
activation (46) 46
chromobacterium-violaceum no-968 (46) 46
depsipeptides - isolation & purification (46) 46
depsipeptides - pharmacokinetics (46) 46
natural-products (46) 46
biotechnology & applied microbiology (45) 45
cell biology (45) 45
hydroxamic acids - pharmacology (45) 45
peptides, cyclic - chemistry (45) 45
antineoplastic agents - adverse effects (44) 44
cells (44) 44
cytotoxicity (44) 44
fusarium (44) 44
natural products (44) 44
antimitotic agents (43) 43
lymphoma, t-cell, cutaneous - drug therapy (43) 43
multidisciplinary sciences (43) 43
hydroxamic acids - therapeutic use (42) 42
medicine & public health (42) 42
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (988) 988
Russian (9) 9
Japanese (8) 8
German (6) 6
Chinese (4) 4
French (4) 4
Italian (4) 4
Polish (4) 4
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
Head & Neck, ISSN 1043-3074, 05/2012, Volume 34, Issue 5, pp. 736 - 745
The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy. No effective systemic treatment... 
epidermal growth factor (EGF) | RET | immunomodulator | vascular disrupting agent | multi‐kinase inhibitor | vascular endothelial growth factor (VEGF) | thyroid cancer | histone acetylation | B‐Raf | heat shock protein (HSP) | multi-kinase inhibitor | B-Raf | SURGERY | HISTONE DEACETYLASE INHIBITOR | SUBEROYLANILIDE HYDROXAMIC ACID | ABL TYROSINE KINASE | PROTEASOME INHIBITION | CELL-CYCLE ARREST | VALPROIC ACID | DEPSIPEPTIDE FR901228 | PHASE-II TRIAL | OTORHINOLARYNGOLOGY | IMATINIB MESYLATE | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bibenzyls - therapeutic use | Humans | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Thalidomide - analogs & derivatives | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Valproic Acid - therapeutic use | Depsipeptides - therapeutic use | Imidazoles - therapeutic use | Lactams, Macrocyclic - therapeutic use | Pyrroles - therapeutic use | Pyridines - therapeutic use | Bortezomib | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Piperazines - therapeutic use | Imatinib Mesylate | Sulfonamides - therapeutic use | Thyroid Neoplasms - drug therapy | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Hydroxamic Acids - therapeutic use | Indoles - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Quinolines - therapeutic use | Benzamides | Thalidomide - therapeutic use | Benzoquinones - therapeutic use | Indazoles - therapeutic use | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Clinical cancer research, ISSN 1557-3265, 2009, Volume 15, Issue 12, pp. 3958 - 3969
Journal Article
Blood, ISSN 0006-4971, 12/2011, Volume 118, Issue 24, pp. 6274 - 6283
We report results from a study exploring the combination of romidepsin, bortezomib, and dexamethasone for the treatment of patients with multiple myeloma (MM)... 
APOPTOSIS | CELLS | HISTONE DEACETYLASE INHIBITOR | MOLECULAR SEQUELAE | PHASE-I TRIAL | TARGETS | HIGH-DOSE MELPHALAN | INDUCTION | HEMATOLOGY | DEPSIPEPTIDE FR901228 | VORINOSTAT | Peripheral Nervous System Diseases - chemically induced | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Dexamethasone - adverse effects | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Secondary Prevention | Antineoplastic Agents - administration & dosage | Boronic Acids - therapeutic use | Multiple Myeloma - drug therapy | Anti-Inflammatory Agents - adverse effects | Peripheral Nervous System Diseases - prevention & control | Antineoplastic Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Depsipeptides - therapeutic use | Boronic Acids - administration & dosage | Depsipeptides - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Drug Administration Schedule | Thrombocytopenia - chemically induced | Dexamethasone - therapeutic use | Maximum Tolerated Dose | Multiple Myeloma - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Survival Analysis | Thrombocytopenia - prevention & control | Aged | Multiple Myeloma - prevention & control | Cohort Studies | Depsipeptides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Cell death & disease, ISSN 2041-4889, 2019, Volume 10, Issue 4, pp. 302 - 14
.... Very recently, a role of nuclear actin for DNA damage repair has been proposed, making actin a potential target for cancer therapy in combination with DNA-damaging therapeutics... 
LATRUNCULIN | NUCLEAR ACTIN | JASPLAKINOLIDE | DOUBLE-STRAND BREAKS | ADRIAMYCIN | POLYMERIZATION | CHONDRAMIDES | CANCER | RADIATION | CHEMOTHERAPY | CELL BIOLOGY | Doxorubicin - therapeutic use | Phosphorylation | Humans | Actins - metabolism | Transplantation, Heterologous | Depsipeptides - pharmacology | Bacterial Proteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Ku Autoantigen - genetics | Neoplasms - genetics | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | DNA-Activated Protein Kinase - metabolism | Replication Protein A - genetics | Depsipeptides - therapeutic use | Cell Death - drug effects | Thiazolidines - pharmacology | DNA Damage - drug effects | DNA End-Joining Repair - drug effects | DNA Repair - drug effects | Ku Autoantigen - metabolism | Replication Protein A - metabolism | Mice, SCID | Neoplasms - drug therapy | Thiazolidines - therapeutic use | Bacterial Proteins - pharmacology | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Actins - antagonists & inhibitors | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Mice, Inbred BALB C | HeLa Cells | Neoplasms - pathology | Doxorubicin - pharmacology | Recombination, Genetic - drug effects | DNA-dependent protein kinase | Actin | Therapeutic applications | Homologous recombination | DNA damage | New combinations | Kinases | Doxorubicin | DNA repair | Deoxyribonucleic acid--DNA | Cancer | Life Sciences | Pharmacology | Pharmaceutical sciences
Journal Article
PLoS pathogens, ISSN 1553-7374, 2015, Volume 11, Issue 9, p. e1005142
Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a... 
ACTIVATION | RNA | PERSISTENCE | CD4(+) T-CELLS | MICROBIOLOGY | VIROLOGY | HISTONE DEACETYLASES | ACTIVE ANTIRETROVIRAL THERAPY | IMMUNODEFICIENCY-VIRUS TYPE-1 | STEM-CELL | INFECTION | PARASITOLOGY | VIRAL RESERVOIR | Follow-Up Studies | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | AIDS Vaccines - therapeutic use | Virus Latency - drug effects | AIDS Vaccines - adverse effects | Anti-HIV Agents - administration & dosage | HIV Infections - immunology | Drug Interactions | HIV-1 - physiology | Lymphocytes - immunology | Protein Processing, Post-Translational - drug effects | HIV-1 - isolation & purification | Adult | Anti-HIV Agents - therapeutic use | Female | Depsipeptides - therapeutic use | RNA, Viral - metabolism | Depsipeptides - adverse effects | Biomarkers - metabolism | Lymphocytes - metabolism | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Biomarkers - blood | Histones - blood | Acetylation - drug effects | HIV-1 - immunology | Virus Activation - drug effects | Lymphocytes - drug effects | HIV Infections - drug therapy | Histones - metabolism | Infusions, Intravenous | Viral Load - drug effects | Cohort Studies | Depsipeptides - administration & dosage | HIV Infections - metabolism | Studies | Plasma | HIV | Acquired immune deficiency syndrome | Cytokines | Lymphocytes | Curing | AIDS | Infections | Human immunodeficiency virus | Research | Drug therapy
Journal Article
Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 4, pp. 397 - 407
Journal Article
International journal of molecular sciences, ISSN 1661-6596, 03/2018, Volume 19, Issue 3, p. 919
...International Journal of Molecular Sciences Review Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides Hee Kyoung Kang 1, Moon... 
Antiproliferative | Marine organism | Therapeutic agents | Anticancer | Peptide | peptide | BIOACTIVE PEPTIDES | MULTICENTER PHASE-II | NATURAL-PRODUCTS | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUBULIN POLYMERIZATION | antiproliferative |